Table 4. Summary of efficacy endpoints - 5 years by estrogen receptor status from diagnosis; ER: Estrogen Receptor.
| All patients (n = 236) |
ER + (n = 124) | ER − (n = 111) | Hazard Ratio | p | |
|---|---|---|---|---|---|
| 5-Year Overall Survival | 77.4% (70.2, 83.1) | 85.5% (75.3, 91.7) | 69.1% (57.7, 78.0) | 2.97 (1.59, 5.56) | 0.001 |
| 5-Year Event-free Survival | 63.7% (55.8, 70.5) | 70.7% (59.7, 79.2) | 56.5% (44.7, 66.6) | 2.02 (1.26, 3.26) | 0.004 |
| 5-Year Breast Cancer Specific Survival | 80.3% (73.7, 86.1) | 87.5% (78.8, 93.8) | 72.0% (61.9, 81.4) | 3.08 (1.58, 6.00) | 0.001 |
| Odds Ratio | p | ||||
| Total pCR Rate (n = 230) | 19.7% (45) | 16.4% (20) | 23.4% (25) | 1.55 (0.81, 3.00) | 0.187 |
| Breast pCR Rate | 23.3% (55) | 18.6% (23) | 28.8% (32) | 1.78 (0.97, 3.28) | 0.065 |